Adriamycin and mitomycin C: Possible synergistic cardiotoxicity

A. U. Buzdar, S. S. Legha, C. K. Tashima, G. N. Hortobagyi, H. Y. Yap, A. N. Krutchik, M. A. Luna, G. R. Blumenschein

Research output: Contribution to journalArticlepeer-review

58 Scopus citations


91 Patients with advanced breast cancer failing adriamycin (ADR)-containing combination chemotherapy were treated with a combination of mitomycin C (MMC) and megestrol acetate. Congestive heart failure (CHF) occurred in 14 (15.3%) of 91 MMC-treated patients compared to three (3.4%) of 89 patients treated with similar ADR-containing combination chemotherapy without MMC (P=0.01). The median time from the last dose of ADR to evidence of CHF was 8.5 months for the MMC group compared to 1.5 months for the other group. A significantly higher incidence of late onset of CHF implicates MMC as a possible cardiotoxic agent.

Original languageEnglish (US)
Pages (from-to)1005-1008
Number of pages4
JournalCancer Treatment Reports
Issue number7
StatePublished - Dec 1 1978
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adriamycin and mitomycin C: Possible synergistic cardiotoxicity'. Together they form a unique fingerprint.

Cite this